Proteomics

Dataset Information

0

Nanobodies peptide/glycopeptide identification


ABSTRACT: Confirmation of Nanobody sequences and identification of Nanobody glycopeptide glycoforms.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Lama Glama

SUBMITTER: Nichollas Scott  

LAB HEAD: Associate Professor Wai-Hong Tham

PROVIDER: PXD023483 | Pride | 2021-09-09

REPOSITORIES: pride

Dataset's files

Source:
Action DRS
Nsco_1482_WHT_Byonic.zip Other
Nsco_1482_WHT_WNB_15_FC.raw Raw
Nsco_1482_WHT_WNB_2_FC.raw Raw
Nsco_1482_WHT_WNB_36_FC.raw Raw
Nsco_1482_WHT_WNB_7_FC.raw Raw
Items per page:
1 - 5 of 6
altmetric image

Publications

Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice.

Pymm Phillip P   Adair Amy A   Chan Li-Jin LJ   Cooney James P JP   Mordant Francesca L FL   Allison Cody C CC   Lopez Ester E   Haycroft Ebene R ER   O'Neill Matthew T MT   Tan Li Lynn LL   Dietrich Melanie H MH   Drew Damien D   Doerflinger Marcel M   Dengler Michael A MA   Scott Nichollas E NE   Wheatley Adam K AK   Gherardin Nicholas A NA   Venugopal Hariprasad H   Cromer Deborah D   Davenport Miles P MP   Pickering Raelene R   Godfrey Dale I DI   Purcell Damian F J DFJ   Kent Stephen J SJ   Chung Amy W AW   Subbarao Kanta K   Pellegrini Marc M   Glukhova Alisa A   Tham Wai-Hong WH  

Proceedings of the National Academy of Sciences of the United States of America 20210501 19


Neutralizing antibodies are important for immunity against SARS-CoV-2 and as therapeutics for the prevention and treatment of COVID-19. Here, we identified high-affinity nanobodies from alpacas immunized with coronavirus spike and receptor-binding domains (RBD) that disrupted RBD engagement with the human receptor angiotensin-converting enzyme 2 (ACE2) and potently neutralized SARS-CoV-2. Epitope mapping, X-ray crystallography, and cryo-electron microscopy revealed two distinct antigenic sites a  ...[more]

Similar Datasets

2024-07-12 | PXD043122 | Pride
2024-05-23 | PXD047734 | Pride
2022-12-01 | PXD028607 | Pride
2022-11-04 | PXD025523 | Pride
2024-08-15 | PXD039831 | Pride
2024-08-15 | PXD039832 | Pride
2022-10-15 | PXD033713 | Pride
2022-10-15 | PXD033642 | Pride
2021-07-21 | PXD023755 | Pride
2024-07-12 | PXD044398 | Pride